Article Information
History
- April 21, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Freddy A. Medina1,*,
- Frances Vila1,
- Laura E. Adams1,
- Jaime Cardona1,
- Jessica Carrion1,
- Elaine Lamirande3,
- Luz N. Acosta1,
- Carlos M. De León-Rodríguez1,
- Manuela Beltran1,
- Demian Grau1,
- Vanessa Rivera-Amill2,
- Angel Balmaseda4,5,
- Eva Harris6,
- Zachary J. Madewell1,
- Stephen H. Waterman1,
- Gabriela Paz-Bailey1,
- Stephen Whitehead3 and
- Jorge L. Muñoz-Jordán1
- 1Centers for Disease Control and Prevention (CDC), San Juan, PR, USA
- 2Ponce Health Sciences University/Ponce Research Institute, Ponce, PR, USA
- 3National Institutes of Health (NIH), Bethesda, MD, USA
- 4Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua
- 5Sustainable Sciences Institute, Managua, Nicaragua
- 6Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California USA
- ↵*Corresponding author; email: fkt3{at}cdc.gov
Posted April 21, 2024.
Comparison of the Sensitivity and Specificity of Commercial Anti-Dengue Virus IgG Tests to Identify Persons Eligible for Dengue Vaccination
